Information on the vaccines approved in Germany, the approved vaccine doses and the vaccine base composition for the 2021/2022 season
The basic composition of the influenza vaccines has to be adapted to the current epidemiological situation every year because the properties of the circulating influenza viruses change. The exact composition is determined each year by the World Health Organization (WHO). This adjustment is checked for each vaccine in a procedure to change the approval. After approval of the strain adaptation, the Paul-Ehrlich-Institut tests and releases the manufactured influenza vaccines in batches, which can then be put on the market and used.
Stand/ as of: 28.11.2021 (Quelle / Source: Paul-Ehrlich-Institut)
| Date | Calendar- week | Number of Doses of Vaccines (total Number) |
|---|---|---|
| 28.11.2021 | 47 | aprox 34.2 Million |
| 21.11.2021 | 46 | aprox 33.8 Million |
| 14.11.2021 | 45 | aprox 33.8 Million |
| 07.11.2021 | 44 | aprox 33 Million |
| 31.10.2021 | 43 | aprox 32.2 Million |
| 24.10.2021 | 42 | aprox 29.8 Million |
| 17.10.2021 | 41 | aprox 28.9 Million |
| 10.10.2021 | 40 | aprox 25 Million |
| 03.10.2021 | 39 | aprox 22.8 Million |
| 26.09.2021 | 38 | aprox. 22.5 Million |
| 19.09.2021 | 37 | aprox. 18.9 Million |
| 12.09.2021 | 36 | aprox. 16.8 Million |
| 05.09.2021 | 35 | aprox. 13 Million |
| 29.08.2021 | 34 | aprox. 10.7 Million |
| 22.08.2021 | 33 | aprox. 10.2 Million |
| 15.08.2021 | 32 | aprox. 7.3 Million |
| 08.08.2021 | 31 | aprox. 4.8 Million |
The influenza vaccine for the 2021/2022 season is composed of the antigens of globally circulating variants of viruses according to the recommendations of the WHO and the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).
This composition differs from that of the 2020/2021 season.
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Victoria/2570/2019 (H1N1)pdm09-like virus |
|
| A/Cambodia/e0826360/2020 (H3N2)-like virus |
|
| B/Washington/02/2019 (B/Victoria lineage)-like virus |
|
| B/Phuket/3073/2013 - like virus (B/Yamagata lineage) |
|
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Wisconsin/588/2019 (H1N1)pdm09-like virus | A/Washington/19/2020 (wild type) |
| A/Cambodia/e0826360/2020 (H3N2)-like virus | A/Tasmania/503/2020 (wild type) |
| B/Washington/02/2019 (B/Victoria lineage)-like virus | B/Darwin/7/2019 (wild type) |
| B/Phuket/3073/2013 - like virus (B/Yamagata lineage) | B/Singapore/INFTT-16-0610/2016 (wild type) |
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Victoria/2570/2019 (H1N1)pdm09-like virus | Virus MEDI 340505, derived from A/Victoria/1/2020 |
| A/Cambodia/e0826360/2020 (H3N2)-like virus | Virus MEDI 339018, derived from A/Tasmania/503/2020 |
| B/Washington/02/2019 (B/Victoria lineage)-like virus | Virus MEDI 323797, derived from B/Washington/02/2019 |
| B/Phuket/3073/2013 - like virus (B/Yamagata lineage) | Virus MEDI 306444, derived from B/Phuket/3073/2013 |
* A and B denote the virus types, the place name refers to the place of virus isolation; the first digit indicates the number of the isolated strain, the second refers to the year of isolation. H and N are the two most important proteins in the virus envelope hemagglutinin and neuraminidase, the number behind them indicates the hemagglutinin and neuraminidase subtype.
Updated: 13.04.2022
